Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy

Rhea-AI Summary

Guardant Health has partnered with Susan G. Komen to enhance breast cancer care. This collaboration aims to develop clinical studies focusing on high-risk early-stage breast cancer patients, utilizing Guardant Reveal™, a blood test for detecting minimal residual disease (MRD). By integrating input from patient advocates, the partnership seeks to create patient-centric research that informs treatment strategies. The initiative aligns with the goal of improving outcomes through personalized cancer monitoring and therapy.

Positive

• Partnership with Susan G. Komen to enhance clinical studies in breast cancer.
• Focus on developing data for Guardant Reveal™, a test for minimal residual disease detection.
• Incorporation of patient perspectives aims to improve research outcomes and clinical approach.

Negative

• None.

• Collaboration will help researchers understand value of monitoring breast cancer patients for residual or recurring disease with Guardant Reveal™ blood test
• Susan G. Komen Advocates in Science will provide patient perspective to inform design of research studies and strategies for personalized cancer care

PALO ALTO, Calif. & DALLAS--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Susan G. Komen®, the world’s leading breast cancer organization, announced today that they have entered into a partnership to bring the patient perspective to the development of clinical studies that help identify early-stage breast cancer patients who are at high risk of disease recurrence and may benefit from additional monitoring or therapy.

The focus of the partnership will be to support the development of clinical utility data for Guardant Reveal™, a blood test for the detection of minimal residual disease (MRD) in patients with early-stage breast cancer. The test detects circulating tumor DNA (ctDNA) in the blood as a measurement of MRD, the presence of which indicates a high risk for disease recurrence.

A critical element of the partnership is the use of input from patient advocates to guide the research study design. These advocates, who serve as Susan G. Komen Advocates in Science, will provide a first-hand perspective of what matters most to patients with early-stage breast cancer in the development of research to find more effective approaches to their care.

“Susan G. Komen’s partnership with Guardant will help us achieve our goal of conquering deadly and aggressive breast cancers and saving lives by moving us towards personalized treatment through identifying which patients are at higher risk for recurrence,” said Victoria Wolodzko Smart, SVP of Mission at Susan G. Komen. “By involving patient advocates in study design, we can achieve truly patient-centric research, clinical trials and treatment, bringing us closer to the goal of improving care and outcomes for all patients.”

“We’re excited to partner with Susan G. Komen to help ensure a patient-centered approach to research for breast cancer patients,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Leveraging their knowledge and resources will help us accelerate the understanding of the clinical value of MRD monitoring and how to personalize care to the specific needs of each patient with early-stage breast cancer to help improve outcomes.”

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221221005074/en/

Guardant Health Contacts:

Investor Contact:

Alex Kleban

investors@guardanthealth.com

+1 657-254-5417

Media Contact:

Michele Rest

press@guardanthealth.com

+1 215-910-2138

Susan G. Komen Contact:

Amanda Skahan

askahan@komen.org

+1 972 701 2131

Source: Guardant Health, Inc.

FAQ

What is the purpose of the collaboration between Guardant Health and Susan G. Komen?

The collaboration aims to enhance clinical studies for early-stage breast cancer patients at high risk of recurrence, using patient input to inform research.

How does Guardant Reveal™ test contribute to breast cancer care?

Guardant Reveal™ detects minimal residual disease (MRD) through circulating tumor DNA in blood, helping identify patients needing further monitoring or therapy.

What role do patient advocates play in this partnership?

Patient advocates provide critical input to guide study design and ensure that research is patient-centric, focusing on the needs and concerns of breast cancer patients.

What are the potential benefits of this partnership for patients?

The partnership aims to improve personalized treatment options and outcomes for breast cancer patients through targeted monitoring and therapy.

What is the significance of monitoring minimal residual disease in breast cancer?

Monitoring MRD is significant as its presence indicates a higher risk for disease recurrence, enabling timely interventions.